论文部分内容阅读
目的初步探讨Arc check调强剂量验证系统在全身照射(TBI)螺旋断层放射治疗剂量验证中的意义。方法将9例TBI患者的螺旋断层放疗计划移植到Arc check调强剂量验证系统和螺旋断层放疗系统标配的Cheese Phantom二维剂量验证系统上进行点剂量及γ通过率的剂量验证。用Pearson相关分析法检验两个验证系统点剂量与γ通过率的相关性,并用配对t检验方法检验其优劣性。结果 Arc check剂量验证系统和Cheese Phantom二维剂量验证系统的点剂量测量值与计算结果的平均误差分别为1.5%和1.7%。采用3%/3 mm标准的平均γ通过率分别为97.7%和95.2%。两个验证系统点剂量的R2值为0.896(P<0.01),γ通过率的R2值为0.832(P<0.01),且两个验证系统的验证结果呈正相关。但两个验证系统的验证结果比较差异无统计学意义(P=0.132,P=0.085)。结论 Arc check能很好地用于TBI螺旋断层放疗剂量验证工作,为以后的TBI剂量验证提供准确的临床质量保证。
Objective To investigate the significance of Arc check enhanced dose verification system in dose-response of whole-body radiation (TBI) spiral CT. Methods Nine cases of TBI were treated with dose-dependent and γ-dose dose transplanted on a Cheese Phantom two-dimensional dose-verification system equipped with Arc check and dose-response system. Pearson correlation analysis was used to test the correlation between point dose and γ pass rate of the two verification systems and the paired t test was used to test the advantages and disadvantages. Results The average error between point dose measurements and calculated results for the Arc check and Cheese Phantom two-dose dose verification systems was 1.5% and 1.7%, respectively. The average γ pass rates using the 3% / 3 mm standard were 97.7% and 95.2%, respectively. The R2 value of the two validation systems was 0.896 (P <0.01), and the R2 value of the γ-pass rate was 0.832 (P <0.01), and the validation results of the two validation systems were positively correlated. However, the validation results of the two validation systems showed no significant difference (P = 0.132, P = 0.085). Conclusion Arc check can be used well in the dose verification of TBI helical CT to provide accurate clinical quality assurance for TBI dose verification.